ArticleScientific reports2026
Mitophagy-driven prognosis in pediatric acute myeloid leukemia: a new frontier.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Mitophagy is a selective form of autophagy that plays a crucial role in mitochondrial quality control. Mediators of the mitophagy pathway have been reported to contribute to tumor progression in multiple solid tumors. Limited data suggests that the overexpression of certain pathway components may predict for adverse survival outcomes in adult AML. However, the role of these mediators in pediatric AML has not been studied previously. We identified nine mitophagy-related genes (PINK1, PARKIN, SQSTM1, NDP52, OPTN, ULK1, MAP1LC3B, FUNDC1, and BNIP3) using the Reactome pathway database and Ensembl genome browser. Gene expression for each of the nine genes was quantified using quantitative reverse transcription polymerase chain reaction on bone marrow mononuclear cells in a retrospective cohort of 90 children (aged ≤ 18 years) with AML and 30 controls. Differential expression of these genes between patients and controls and across different molecular subtypes was assessed using nonparametric statistical tests. For external validation, transcriptomic data from children and young adults (aged ≤ 39 years) with AML and control samples from the Beat AML cohort were also analyzed. Survival analyses were performed using Kaplan-Meier estimates, and log-rank tests were used to evaluate associations between gene expression (upper versus lower quartiles) and relapse-free and overall survival in our patient cohort. A total of 90 children with AML patients and 30 controls were included. All nine mitophagy-related genes were significantly overexpressed in AML compared with controls, which was independently confirmed in the Beat AML cohort. Upregulation of all nine genes was consistent across most subgroups examined. Among these genes, only FUNDC1 overexpression was significantly associated with inferior relapse-free survival (HR = 2.039, p = 0.044). Mitophagy-related genes are upregulated across pediatric AML subtypes. FUNDC1 expression overexpression is associated with inferior relapse-free survival (RFS). Identifying vulnerabilities in mitophagy pathways may open avenues for therapeutic targeting in pediatric AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.